SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Nov 1, 2013
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Nov. 1, 2013 · CIK: 0001503802 · Accession: 0001104659-13-080011
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191584
Letter
KARYOPHARM THERAPEUTICS INC.
2 Mercer Road
Natick, MA 01760
November 1, 2013
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Karyopharm Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-191584
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-191584), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 5, 2013, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Securities and Exchange Commission (the “Commission”).
The Registrant hereby acknowledges that:
(i) should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
[Signature page follows]
Very truly yours,
KARYOPHARM THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm KARYOPHARM THERAPEUTICS INC. 2 Mercer Road Natick, MA 01760 November 1, 2013 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-1 File No. 333-191584 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-191584), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 5, 2013, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Securities and Exchange Commission (the “Commission”). The Registrant hereby acknowledges that: (i) should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. [Signature page follows] Very truly yours, KARYOPHARM THERAPEUTICS INC. By: /s/ Paul Brannelly Paul Brannelly Senior Vice President, Finance and Administration 2